• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IMPeTUs参数与新诊断多发性骨髓瘤的临床特征相关。

IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma.

作者信息

Xu Shuaishuai, Jiao Shengxiu, Guo Huimin, Chen Wenkun, Yao Shuzhan

机构信息

Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.

出版信息

Eur J Radiol Open. 2024 Sep 3;13:100598. doi: 10.1016/j.ejro.2024.100598. eCollection 2024 Dec.

DOI:10.1016/j.ejro.2024.100598
PMID:39296251
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11408006/
Abstract

OBJECTIVES

To investigate the correlations between IMPeTUs-based 18 F-FDG PET/CT parameters and clinical features in patients with newly diagnosed multiple myeloma (MM).

MATERIALS AND METHODS

PET/CT were analysed according to the IMPeTUs criteria. We correlated these PET/CT parameters with known clinically relevant features, bone marrow plasma cell (BMPC) infiltration rate and the presence of cytogenetic abnormalities.

RESULTS

A total of 149 patients (86 males, 63 females; mean age, 59.9 ± 9.7 years) were included. Bone marrow metabolic state correlated with the most clinical features including hemoglobin (rho=-0.23, p=0.004), FLC ratio (rho=0.24, p=0.005), β2 M (rho=0.28, p=0.001), CRP (rho=0.25, p=0.003), serum calcium (rho=0.22, p=0.02), serum creatinine (rho=0.24, p=0.004) and BMPC (rho=0.21, p=0.003). Besides, the level of hemoglobin was significant lower (0.043), and the levels of FLC ratio (0.037), β2 M (p=0.024), CRP (p=0.05), and BMPC (p=0.043) were significant higher in patients having hypermetabolism in limbs and ribs. Hottest bone lesion Deauville criteria had a moderate correlation with CRP (rho=0.27, p=0.001) and serum calcium (rho=0.25, p=0.01).

CONCLUSION

Several IMPeTUs-based PET/CT parameters showed significant correlations with clinical features reflecting disease burden and biology, suggesting that these new criteria can be used in the risk stratification in MM patients.

摘要

目的

探讨基于IMPeTUs的18F-FDG PET/CT参数与新诊断的多发性骨髓瘤(MM)患者临床特征之间的相关性。

材料与方法

根据IMPeTUs标准分析PET/CT。我们将这些PET/CT参数与已知的临床相关特征、骨髓浆细胞(BMPC)浸润率和细胞遗传学异常的存在情况进行关联。

结果

共纳入149例患者(男性86例,女性63例;平均年龄59.9±9.7岁)。骨髓代谢状态与大多数临床特征相关,包括血红蛋白(rho=-0.23,p=0.004)、游离轻链比值(rho=0.24,p=0.005)、β2微球蛋白(rho=0.28,p=0.001)、C反应蛋白(rho=0.25,p=0.003)、血清钙(rho=0.22,p=0.02)、血清肌酐(rho=0.24,p=0.004)和BMPC(rho=0.21,p=0.003)。此外,四肢和肋骨代谢亢进的患者血红蛋白水平显著降低(0.043),游离轻链比值(0.037)、β2微球蛋白(p=0.024)、C反应蛋白(p=0.05)和BMPC(p=0.043)水平显著升高。最热骨病变的Deauville标准与C反应蛋白(rho=0.27,p=0.001)和血清钙(rho=0.25,p=0.01)有中度相关性。

结论

几个基于IMPeTUs的PET/CT参数与反映疾病负担和生物学特性的临床特征显示出显著相关性,表明这些新标准可用于MM患者的风险分层。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/7bc1b34549f0/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/7527a46a8bbb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/5de15f255dee/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/fcd0415c05c0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/229e540b0567/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/7bc1b34549f0/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/7527a46a8bbb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/5de15f255dee/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/fcd0415c05c0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/229e540b0567/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/744d/11408006/7bc1b34549f0/gr5.jpg

相似文献

1
IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma.IMPeTUs参数与新诊断多发性骨髓瘤的临床特征相关。
Eur J Radiol Open. 2024 Sep 3;13:100598. doi: 10.1016/j.ejro.2024.100598. eCollection 2024 Dec.
2
The prognostic significance of [F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs).根据新的解读标准(IMPeTUs),[F]FDG PET/CT在多发性骨髓瘤中的预后意义。
EJNMMI Res. 2021 Oct 9;11(1):100. doi: 10.1186/s13550-021-00846-y.
3
Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [F]FDG PET/CT predicts survival in multiple myeloma.基于人工智能的 [F]FDG PET/CT 骨髓代谢活性容积评估可预测多发性骨髓瘤的生存情况。
Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2293-2307. doi: 10.1007/s00259-024-06668-z. Epub 2024 Mar 8.
4
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).多发性骨髓瘤中FDG PET/CT的图像解读标准:来自意大利专家小组的新提议。IMPeTUs(意大利PET使用的骨髓瘤标准)
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.
5
Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [F]FDG PET/CT in patients with newly diagnosed multiple myeloma.视觉IMPeTUs标准及基线[F]FDG PET/CT代谢肿瘤负荷对新诊断多发性骨髓瘤患者的预后价值
EJNMMI Res. 2024 May 28;14(1):51. doi: 10.1186/s13550-024-01113-6.
6
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).FDG PET/CT 多发性骨髓瘤解读标准(IMPeTUs):最终结果。IMPeTUs(意大利多发性骨髓瘤 PET 使用标准)。
Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21.
7
Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.多发性骨髓瘤患者基线18F-FDG PET/CT检查结果与骨髓中表达CD38和CD138的骨髓瘤细胞及临床参数之间的相关性
Turk J Haematol. 2018 Aug 3;35(3):175-180. doi: 10.4274/tjh.2017.0372. Epub 2018 May 28.
8
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.一种提议的弥漫性骨髓[18F]-FDG摄取指数及PET骨骼模式与骨髓瘤预后标志物、浆细胞形态及治疗反应相关。
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1487-1497. doi: 10.1007/s00259-020-05078-1. Epub 2020 Oct 25.
9
Comparison between tumour metabolism derived from F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients.初诊多发性骨髓瘤患者中基于F-FDG PET/CT的肿瘤代谢与精确细胞遗传学分层的比较
Quant Imaging Med Surg. 2021 Oct;11(10):4299-4309. doi: 10.21037/qims-21-85.
10
18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features.18F-氟代脱氧葡萄糖、11C-蛋氨酸和68Ga-喷替沙福PET/CT在冒烟型多发性骨髓瘤患者中的应用:影像表现和临床特征
Cancers (Basel). 2020 Aug 18;12(8):2333. doi: 10.3390/cancers12082333.

本文引用的文献

1
Multitracer PET/CT with [F]Fluorodeoxiglucose and [F]Fluorocholine in the Initial Staging of Multiple Myeloma Patients Applying the IMPeTus Criteria: A Pilot Study.采用IMPeTus标准,利用[F]氟脱氧葡萄糖和[F]氟胆碱进行多示踪剂PET/CT对多发性骨髓瘤患者进行初始分期:一项试点研究。
Diagnostics (Basel). 2023 Apr 27;13(9):1570. doi: 10.3390/diagnostics13091570.
2
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.多发性骨髓瘤:2022 年诊断、风险分层和治疗的更新。
Am J Hematol. 2022 Aug;97(8):1086-1107. doi: 10.1002/ajh.26590. Epub 2022 May 23.
3
New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms: The Light Leading Out of the Darkness in Challenging Tumors.
基于多示踪剂 PET/CT 成像的神经内分泌肿瘤具有预后影响的新型生物标志物:在具有挑战性的肿瘤中走出黑暗的光明。
Clin Nucl Med. 2022 Mar 1;47(3):219-220. doi: 10.1097/RLU.0000000000004062.
4
The prognostic significance of [F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs).根据新的解读标准(IMPeTUs),[F]FDG PET/CT在多发性骨髓瘤中的预后意义。
EJNMMI Res. 2021 Oct 9;11(1):100. doi: 10.1186/s13550-021-00846-y.
5
Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value.多发性骨髓瘤患者的 PET-CT 骨髓示踪剂摄取模式:图像解读与预后价值。
Ann Hematol. 2021 Dec;100(12):2979-2988. doi: 10.1007/s00277-021-04629-2. Epub 2021 Aug 20.
6
Standardization of F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.根据 Deauville 标准对新诊断多发性骨髓瘤代谢完全缓解定义的 F-FDG-PET/CT 标准化。
J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.
7
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.一种提议的弥漫性骨髓[18F]-FDG摄取指数及PET骨骼模式与骨髓瘤预后标志物、浆细胞形态及治疗反应相关。
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1487-1497. doi: 10.1007/s00259-020-05078-1. Epub 2020 Oct 25.
8
PET-FDG: Impetus.正电子发射断层显像-氟代脱氧葡萄糖:动力。
Cancers (Basel). 2020 Apr 22;12(4):1030. doi: 10.3390/cancers12041030.
9
Medullary Abnormalities in Appendicular Skeletons Detected With F-FDG PET/CT Predict an Unfavorable Prognosis in Newly Diagnosed Multiple Myeloma Patients With High-Risk Factors.F-FDG PET/CT 检测到附肢骨骼中的骨髓异常可预测伴有高危因素的初诊多发性骨髓瘤患者的不良预后。
AJR Am J Roentgenol. 2019 Oct;213(4):918-924. doi: 10.2214/AJR.19.21283. Epub 2019 Jun 19.
10
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.国际骨髓瘤工作组关于单克隆浆细胞疾病影像学的共识建议。
Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2.